Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storage

Autor:	Jose A, Cancelas, Sherrill J, Slichter, Neeta, Rugg, P Gayle, Pratt, Shawnagay, Nestheide, Jill, Corson, Esther, Pellham, Marty, Huntington, Raymond P, Goodrich
Rok vydání:	2016
Předmět:	Adult Male Cross-Over Studies Erythrocytes Cell Survival Ultraviolet Rays Blood Safety Riboflavin Hemolysis Disinfection Blood Blood Preservation Humans Female Single-Blind Method Prospective Studies
Zdroj:	Transfusion. 57(5)
ISSN:	1537-2995
Popis:	Pathogen reduction (PR) of whole blood (WB) may increase blood safety when applied before component separation. This study evaluates the in vivo performance of red blood cells (RBCs) derived from WB treated with the riboflavin and ultraviolet (UV) light PR (Mirasol) system.This was a prospective, two-center, single-blind, randomized, two-period, crossover clinical trial designed to evaluate autologousTwenty-four healthy adult volunteers (n = 12 per site) were evaluated. The Mirasol 24-hr RBC recoveries were 82.5 ± 3.9% with one-sided 95% lower confidence limit of 80.9%, meeting US Food and Drug Administration acceptance criteria, albeit at lower level than controls (91.7 ± 6.8%, p 0.001). Mean RBC survival and TRBCs derived from Mirasol WB and stored for up to 21 days in AS-3 maintained acceptable cell quality and recovery, albeit modestly reduced compared with untreated RBCs. Mirasol WB may represent a valid single WB PR platform that allows manufacture of RBC for storage for up to 21 days.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=pmid________::5967edb2729dce49b634e5d0649b8f7b https://pubmed.ncbi.nlm.nih.gov/28369971 Zobrazit plný text záznamu Plný text